SCHEMBL26579386

SCHEMBL26579386

Cc1ccc(CCN2Cc3c(cc(C)c(Br)c3O)C2=O)cc1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CNR2 P34972 5/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ CA1 P00915 1/20 0.36
▸ CA2 P00918 1/20 0.36
▸ CA4 P22748 1/20 0.36
▸ CA9 Q16790 1/20 0.36
▸ DAO P14920 1/20 0.35
▸ CARM1 Q86X55 1/20 0.35
▸ HRH3 Q9Y5N1 1/20 0.35
▸ BRD4 O60885 1/20 0.35
▸ BRDT Q58F21 1/20 0.35
▸ TP53 P04637 2/20 0.34
▸ MAPT P10636 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ ADRA1D P25100 1/20 0.34
▸ ADRA1A P35348 1/20 0.34
▸ ADRA1B P35368 1/20 0.34
▸ POLB P06746 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26579408 0.91 PTGS1 (0.41) CNR2SMN1; SMN2POLB
SCHEMBL26579422 0.89 CNR2 (0.46) CNR2DAOHRH3
SCHEMBL26579416 0.88 CNR2 (0.39) CNR2DAOADRA1DADRA1AADRA1B
SCHEMBL26579398 0.84 CNR2 (0.40) CNR2SMN1; SMN2CA1CA2CA4
SCHEMBL26579407 0.83 CNR2 (0.42) CNR2SMN1; SMN2CA1CA2CA4
SCHEMBL26579389 0.81 CNR2 (0.43) CNR2SMN1; SMN2CA1CA2CA4
SCHEMBL25904078 0.78 CNR2 (0.46) CNR2DAOHRH3TP53MAPT
SCHEMBL25903272 0.77 CNR2 (0.50) CNR2DAOHRH3TP53MAPT
SCHEMBL26579484 0.77 CNR2 (0.49) CNR2MAPT
SCHEMBL26579430 0.72 CASR (0.42) CNR2SMN1; SMN2CARM1TP53MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230331672-A1 6-METHOXY-2-PHENETHYL ISOINDOLINE-1-ONE DERIVATIVE AND COMPOSITION FOR TREATING NEUROLOGICAL DISORDERS, COMPRISING SAME CNG BIO CO., LTD. (KR) 2023-10-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230331672-A1 6-METHOXY-2-PHENETHYL ISOINDOLINE-1-ONE DERIVATIVE AND COMPOSITION FOR TREATING NEUROLOGICAL DISORDERS, COMPRISING SAME NGF, BDNF, NTRK2 CNR2 412/4885SMN1; SMN2 4/4885CA1 3478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback